Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE …

PJ Mease, S Cohen, NB Gaylis, A Chubick… - The Journal of …, 2010 - jrheum.org
Objective. To assess the efficacy and safety of 1 versus 2 courses of rituximab over 48 weeks
in patients with rheumatoid arthritis (RA). Methods. Adult patients taking methotrexate with …

Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage …

MC Genovese, NB Gaylis, D Sikes, A Kivitz… - The Lancet …, 2020 - thelancet.com
Background The inflammatory reflex plays a role in regulating innate and adaptive immunity
by modulating cellular and molecular inflammatory pathways. The vagus nerve is a major …

Reduced cell surface levels of CC chemokine receptor 5 and immunosuppression in long coronavirus disease 2019 syndrome

NB Gaylis, A Ritter, SA Kelly… - Clinical Infectious …, 2022 - academic.oup.com
In an exploratory trial treating “long COVID” with the CCR5-binding antibody leronlimab, we
observed significantly increased blood cell surface CCR5 in treated symptomatic …

[HTML][HTML] Switching to biosimilar SDZ-ADL in patients with moderate-to-severe active rheumatoid arthritis: 48-week efficacy, safety and immunogenicity results from the …

…, A Thakur, H Haliduola, I Brueckmann, NB Gaylis - BioDrugs, 2020 - Springer
Background Sandoz adalimumab SDZ-ADL (GP-2017) is an approved adalimumab biosimilar
with similar efficacy and comparable safety and immunogenicity to reference adalimumab …

Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a …

…, JR Curtis, U Müller-Ladner, NB Gaylis… - …, 2011 - academic.oup.com
Objective. To assess the efficacy and safety profiles of two different rituximab retreatment
regimens in patients with RA. Methods. Four hundred and ninety-three RA patients with an …

[HTML][HTML] Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study

…, MW Greenwald, JM Kremer, NB Gaylis… - BMC Musculoskeletal …, 2014 - Springer
Background As recommended in the current prescribing information, rituximab infusions in
patients with rheumatoid arthritis (RA) take 4.25 hours for the first infusion and 3.25 hours for …

[HTML][HTML] Monitoring cartilage loss in the hands and wrists in rheumatoid arthritis with magnetic resonance imaging in a multi-center clinical trial: IMPRESS …

…, JT Merrill, PJ Countryman, NB Gaylis - Arthritis Research & …, 2013 - Springer
Introduction Magnetic resonance imaging (MRI) is increasingly being used in clinical trials of
rheumatoid arthritis (RA) because of its superiority over x-ray radiography (XR) in detecting …

Cerebral atrophy in systemic lupus erythematosus: steroid-or disease-induced phenomenon?

SG Ostrov, RM Quencer, NB Gaylis… - American Journal of …, 1982 - Am Soc Neuroradiology
Thirty-two patients with systemic lupus erythematosus were evaluated clinically and with
computed tomography in order to determine whether the occurrence of cerebral atrophy in …

Long-term follow-up of an HIV-infected patient with reactive arthritis treated with infliximab

NB Gaylis - JCR: Journal of Clinical Rheumatology, 2012 - journals.lww.com
Tumor necrosis factor>(TNF->), implicated in the patho-physiology of a variety of rheumatic
diseases, 1Y3 may also contribute to HIV propagation, and there are data suggesting clinical …

Magnetic resonance imaging in rheumatoid arthritis clinical trials: emerging patterns based on recent experience

…, A Anisfeld, W Tsuji, E Olech, NB Gaylis… - The Journal of …, 2011 - jrheum.org
Objective. The current validated magnetic resonance imaging (MRI) scoring method for
rheumatoid arthritis (RA) in clinical trials, RA MRI Score (RAMRIS), incorporates all …